UNSPSC 51203300: Immunosupressant phthalimides

This classification denotes imides of phthalic acid(s), substances called phthalimides, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPRESSANT PHTHALIMIDES.

UNSPSC 51203300 Immunosuppressant phthalimides is a Class code that does not match the pharmaceutical and medical supply work currently being solicited under it in state and local procurement. The recent opportunities posted under this code span naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, direct-to-manufacturer prescription programs, and emergency medical and first aid supplies — none of which fall within the immunosuppressant phthalimides therapeutic category. The mismatch suggests either a classification error in the underlying procurement database or that state and local issuing bodies are using this code as a catch-all for broader pharmaceutical and medical product acquisitions rather than limiting it to its narrower intended scope.

Issuing bodies soliciting under the code include county health departments (Seminole County, Florida), state HHS and multistate cooperative purchasing alliances (Texas Health and Human Services Commission, Minnesota Multistate Cooperative Purchasing Alliance with Oregon participation), and city fire and rescue divisions (City of Tampa). The geographic concentration spans Florida, Texas, Minnesota, and Oregon across recent postings. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (IFB60459723LAS); the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs posted April 3, 2026; the City of Tampa's IFB for medical and first aid supplies (169 line items for the Fire Department Rescue Division) with a deadline of March 13, 2026 and an estimated contract value of $700,000.00, sheltered to Small Local Business Enterprises with a 5 percent SLBE bid discount available; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products due March 26, 2026, requiring distribution through specified wholesalers with awards effective July 1, 2026. The code shows activity but lacks a coherent procurement narrative aligned to its nominal immunosuppressant classification.